FDA Grants Fast Track to BlossomHill's BH-30643 for EGFR C797S NSCLC
BLSM is trading near its 52-week low of $15.97 (7.3% above the low).
Summary
The FDA granted Fast Track designation to BH-30643, BlossomHill's macrocyclic OMNI-EGFR inhibitor, for advanced EGFR C797S-positive NSCLC after prior third-generation TKI treatment. This is the first regulatory milestone for the lead asset since the company's IPO on August 7, and it validates the C797S resistance strategy in a population with no approved oral targeted therapies. Fast Track enables more frequent FDA engagement, rolling NDA review, and potential eligibility for accelerated approval. The designation follows strong insider and institutional buying at the IPO, including $10M from OrbiMed and a 13D showing Cormorant's 11.79% stake. Phase 1/2 SOLARA trial is enrolling at 40+ sites across 10 countries, with dose expansion cohorts in both TKI-pretreated and TKI-naïve settings. Next data readout from SOLARA will be the key catalyst for this thesis.
At the time of this announcement, BLSM was trading at $17.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $501.9M. The 52-week trading range was $15.97 to $17.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.